surpass-cvot tirzepatide π« EASD 2025: (SURPASS-CVOT) Dulaglutide head-to-head showdown: β Noninferior for MACE β 16% β all-cause mortality β Superior in A1C & weight loss Tirzepatide confirms its broad cardiometabolic edge. #EASD2025 # Tirzepatide #GLP1 SURPASS-CVOT trial: Tirzepatide was non-inferior
Description
Just finished my first month lost 10 pounds This first month worked very well for appetite suppression, not so much weight loss
95% CI, 8.5-8.8
These findings suggest that GLP modulates the effect of GIP-1 toward the obesogenic effect
Raphas Co
Martin, C
